Correlation Between MEI Pharma and Puma Biotechnology

Can any of the company-specific risk be diversified away by investing in both MEI Pharma and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining MEI Pharma and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between MEI Pharma and Puma Biotechnology, you can compare the effects of market volatilities on MEI Pharma and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in MEI Pharma with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of MEI Pharma and Puma Biotechnology.

Diversification Opportunities for MEI Pharma and Puma Biotechnology

-0.47

Correlation Coefficient

MEI Pharma  Puma Biotechnology

Very good diversification

The 3 months correlation between MEI and Puma is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding MEI Pharma and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and MEI Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MEI Pharma are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of MEI Pharma i.e., MEI Pharma and Puma Biotechnology go up and down completely randomly.

Pair Corralation between MEI Pharma and Puma Biotechnology

Given the investment horizon of 90 days MEI Pharma is expected to under-perform the Puma Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, MEI Pharma is 2.5 times less risky than Puma Biotechnology. The stock trades about 0.0 of its potential returns per unit of risk. The Puma Biotechnology is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  315.00  in Puma Biotechnology on December 25, 2024 and sell it today you would earn a total of  10.00  from holding Puma Biotechnology or generate 3.17% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

MEI Pharma  vs.  Puma Biotechnology

MEI Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days MEI Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward indicators, MEI Pharma is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Puma Biotechnology

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with MEI Pharma and Puma Biotechnology

The main advantage of trading using opposite MEI Pharma and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if MEI Pharma position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.

The idea behind MEI Pharma and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.